CA2322741A1 - Thrombin preparation and products and fibrin sealant methods employing same - Google Patents

Thrombin preparation and products and fibrin sealant methods employing same Download PDF

Info

Publication number: CA2322741A1
Authority: CA; Canada
Prior art keywords: thrombin; prothrombin; fibrinogen; plasma; precipitate
Prior art date: 1998-03-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002322741A

Other languages

English (en)

French (fr)

Inventor

David H. Sierra

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Baxter International Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-10

Filing date

1999-03-10

Publication date

1999-09-16

1999-03-10 Application filed by Baxter International Inc filed Critical Baxter International Inc

1999-09-16 Publication of CA2322741A1 publication Critical patent/CA2322741A1/en

Status Abandoned legal-status Critical Current

Links

108090000190 Thrombin Proteins 0.000 title claims abstract description 105
229960004072 thrombin Drugs 0.000 title claims abstract description 105
108010080379 Fibrin Tissue Adhesive Proteins 0.000 title claims abstract description 34
238000000034 method Methods 0.000 title claims description 59
238000002360 preparation method Methods 0.000 title description 17
108010049003 Fibrinogen Proteins 0.000 claims abstract description 47
102000008946 Fibrinogen Human genes 0.000 claims abstract description 47
229940012952 fibrinogen Drugs 0.000 claims abstract description 46
108010094028 Prothrombin Proteins 0.000 claims abstract description 45
102100027378 Prothrombin Human genes 0.000 claims abstract description 44
229940039716 prothrombin Drugs 0.000 claims abstract description 44
239000000463 material Substances 0.000 claims abstract description 43
210000004369 blood Anatomy 0.000 claims abstract description 27
239000008280 blood Substances 0.000 claims abstract description 27
239000002502 liposome Substances 0.000 claims abstract description 20
125000001095 phosphatidyl group Chemical group 0.000 claims abstract description 12
210000002381 plasma Anatomy 0.000 claims description 47
239000002244 precipitate Substances 0.000 claims description 31
108010073385 Fibrin Proteins 0.000 claims description 28
102000009123 Fibrin Human genes 0.000 claims description 28
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 27
229950003499 fibrin Drugs 0.000 claims description 27
239000000203 mixture Substances 0.000 claims description 25
239000000565 sealant Substances 0.000 claims description 25
239000006228 supernatant Substances 0.000 claims description 19
108010071289 Factor XIII Proteins 0.000 claims description 18
229940012444 factor xiii Drugs 0.000 claims description 17
238000006243 chemical reaction Methods 0.000 claims description 14
239000000758 substrate Substances 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 11
239000012190 activator Substances 0.000 claims description 10
150000003904 phospholipids Chemical class 0.000 claims description 9
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 8
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 8
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 8
210000001519 tissue Anatomy 0.000 claims description 8
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
239000012736 aqueous medium Substances 0.000 claims description 7
108010014172 Factor V Proteins 0.000 claims description 6
239000001110 calcium chloride Substances 0.000 claims description 6
229910001628 calcium chloride Inorganic materials 0.000 claims description 6
230000001413 cellular effect Effects 0.000 claims description 6
229910001424 calcium ion Inorganic materials 0.000 claims description 5
102000004411 Antithrombin III Human genes 0.000 claims description 4
108090000935 Antithrombin III Proteins 0.000 claims description 4
229960005348 antithrombin iii Drugs 0.000 claims description 4
239000003153 chemical reaction reagent Substances 0.000 claims description 4
210000002889 endothelial cell Anatomy 0.000 claims description 4
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
108010014173 Factor X Proteins 0.000 claims description 3
239000007825 activation reagent Substances 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 abstract description 3
239000000243 solution Substances 0.000 description 24
239000000047 product Substances 0.000 description 18
241000283690 Bos taurus Species 0.000 description 12
210000002966 serum Anatomy 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
238000001556 precipitation Methods 0.000 description 8
230000008569 process Effects 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
238000001879 gelation Methods 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
230000004913 activation Effects 0.000 description 5
235000011148 calcium chloride Nutrition 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000012141 concentrate Substances 0.000 description 5
229940067606 lecithin Drugs 0.000 description 5
235000010445 lecithin Nutrition 0.000 description 5
239000000787 lecithin Substances 0.000 description 5
239000002245 particle Substances 0.000 description 5
230000001376 precipitating effect Effects 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 4
102000005686 Serum Globulins Human genes 0.000 description 4
108010045362 Serum Globulins Proteins 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000023597 hemostasis Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
108010027612 Batroxobin Proteins 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
238000013459 approach Methods 0.000 description 3
229960002210 batroxobin Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
238000001914 filtration Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
239000010410 layer Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
108010074864 Factor XI Proteins 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000004623 platelet-rich plasma Anatomy 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000004044 response Effects 0.000 description 2
238000007789 sealing Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000003998 snake venom Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
244000205754 Colocasia esculenta Species 0.000 description 1
235000006481 Colocasia esculenta Nutrition 0.000 description 1
229920001605 Dextranomer Polymers 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000010441 alabaster Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940030225 antihemorrhagics Drugs 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960002864 dextranomer Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
239000002874 hemostatic agent Substances 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
-1 into its active form Proteins 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000002960 lipid emulsion Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
108010015680 recombinant human thrombin Proteins 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000009987 spinning Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940068942 topical hemo-stat Drugs 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Surgery (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

CA002322741A 1998-03-10 1999-03-10 Thrombin preparation and products and fibrin sealant methods employing same Abandoned CA2322741A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7761998P	1998-03-10	1998-03-10
US60/077,619		1998-03-10
PCT/US1999/005034 WO1999045938A1 (en)	1998-03-10	1999-03-10	Thrombin preparation and products and fibrin sealant methods employing same

Publications (1)

Publication Number	Publication Date
CA2322741A1 true CA2322741A1 (en)	1999-09-16

Family

ID=22139138

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002322741A Abandoned CA2322741A1 (en)	1998-03-10	1999-03-10	Thrombin preparation and products and fibrin sealant methods employing same

Country Status (5)

Country	Link
EP (1)	EP1061931A2 (de)
JP (1)	JP2002506038A (de)
AU (1)	AU2900599A (de)
CA (1)	CA2322741A1 (de)
WO (1)	WO1999045938A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113438928A (zh) *	2019-03-06	2021-09-24	甘布罗伦迪亚股份公司	用于递送凝血酶激活的纤维蛋白密封剂的装置和方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000062828A1 (en)	1996-04-30	2000-10-26	Medtronic, Inc.	Autologous fibrin sealant and method for making the same
US6274090B1 (en)	1998-08-05	2001-08-14	Thermogenesis Corp.	Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
US6472162B1 (en)	1999-06-04	2002-10-29	Thermogenesis Corp.	Method for preparing thrombin for use in a biological glue
WO2001045760A1 (en) *	1999-12-22	2001-06-28	Henogen S.A.	Bone generating product
CN102014973A (zh)	2008-02-29	2011-04-13	弗罗桑医疗设备公司	用于促进止血和/或伤口愈合的装置
DE102011112955A1 (de)	2011-09-13	2013-03-14	Medizinische Hochschule Hannover	Verfahren zur Herstellung eines biologischen Gewebekonstrukts und Verwendung spezifisch gewonnener autologer Zellen
RU2657955C2 (ru)	2012-03-06	2018-06-18	Ферросан Медикал Дивайсиз А/С	Контейнер под давлением, содержащий гемостатическую пасту
EP2977066A3 (de)	2012-06-12	2016-07-27	Ferrosan Medical Devices A/S	Trockene blutstillende zusammensetzung
BR112014028068A2 (pt) *	2012-09-25	2017-08-08	Stem Cell Partners Llc	método e aparelho para preparar soro de trombina de doador único
AU2014283170B2 (en)	2013-06-21	2017-11-02	Ferrosan Medical Devices A/S	Vacuum expanded dry composition and syringe for retaining same
JP6489485B2 (ja)	2013-12-11	2019-03-27	フェロサンメディカルデバイシーズエイ／エス	押し出し増強因子を含んでいる乾燥組成物
AU2015333206B2 (en)	2014-10-13	2019-07-11	Ferrosan Medical Devices A/S.	Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru)	2014-12-24	2019-11-12	Ферросан Медикал Дивайсиз А/С	Шприц для удерживания и смешивания первого и второго веществ
CN107771093B (zh)	2015-07-03	2021-06-15	弗罗桑医疗设备公司	用于混合两种组分和用于在存储条件下保持真空的注射器
US11801324B2 (en)	2018-05-09	2023-10-31	Ferrosan Medical Devices A/S	Method for preparing a haemostatic composition
CN112997967A (zh) *	2021-03-09	2021-06-22	复旦大学附属华山医院	一种凝血酶磁珠及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5226877A (en) *	1989-06-23	1993-07-13	Epstein Gordon H	Method and apparatus for preparing fibrinogen adhesive from whole blood
EP0624199B1 (de) *	1991-12-31	1999-05-06	Zymogenetics, Inc.	Verfahren zur Herstellung von Thrombin
US5266462A (en) *	1992-06-03	1993-11-30	Baxter Diagnostics Inc.	Measurement of platelet activities
US5219995A (en) *	1992-07-14	1993-06-15	Alpha Therapeutic Corporation	Plasma fraction purification
US5330974A (en) *	1993-03-01	1994-07-19	Fibratek, Inc.	Therapeutic fibrinogen compositions

1999
- 1999-03-10 JP JP2000535352A patent/JP2002506038A/ja not_active Withdrawn
- 1999-03-10 EP EP99909912A patent/EP1061931A2/de not_active Withdrawn
- 1999-03-10 WO PCT/US1999/005034 patent/WO1999045938A1/en not_active Ceased
- 1999-03-10 AU AU29005/99A patent/AU2900599A/en not_active Withdrawn
- 1999-03-10 CA CA002322741A patent/CA2322741A1/en not_active Abandoned

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113438928A (zh) *	2019-03-06	2021-09-24	甘布罗伦迪亚股份公司	用于递送凝血酶激活的纤维蛋白密封剂的装置和方法

Also Published As

Publication number	Publication date
AU2900599A (en)	1999-09-27
WO1999045938A1 (en)	1999-09-16
JP2002506038A (ja)	2002-02-26
WO1999045938B1 (en)	1999-12-02
EP1061931A2 (de)	2000-12-27

Legal Events

Date	Code	Title	Description
2002-12-04	FZDE	Dead

Publication	Publication Date	Title
CA2322741A1 (en)	1999-09-16	Thrombin preparation and products and fibrin sealant methods employing same
AU678439B2 (en)	1997-05-29	Process for the obtention of a biological adhesive comprising fibrinogen, factor XIII and fibronectin
US5290918A (en)	1994-03-01	Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
US4394373A (en)	1983-07-19	Method of achieving hemostasis
US5099003A (en)	1992-03-24	Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii
JP2511462B2 (ja)	1996-06-26	一成分組織接着剤およびその製造方法
US5605887A (en)	1997-02-25	Therapeutic fibrinogen compositions
US4160025A (en)	1979-07-03	Method of producing a blood-coagulation-promoting preparation from human blood plasma
EP2520316B1 (de)	2018-08-15	Von Blut und Blutfraktionen isoliertes Thrombin
JPH1121249A (ja)	1999-01-26	局所用フィブリノーゲン複合体
JPH06511018A (ja)	1994-12-08	血漿分画精製法
CA2162997A1 (en)	1995-09-28	Topical fibrinogen complex
Zucker et al.	1976	Ultrastructural aspects of interactions of platelets with microcrystalline collagen
JPH02114A (ja)	1990-01-05	トロンビン凝固性蛋白質の濃縮物、その製造方法及びその治療的用途
JPH02129224A (ja)	1990-05-17	フィブリンの製造法
JPH0159280B2 (de)	1989-12-15
Silberstein et al.	1988	An autologous fibrinogen‐based adhesive for use in otologic surgery
Xu et al.	2022	Biomimetic peptide nanoparticles participate in natural coagulation for hemostasis and wound healing
US3862314A (en)	1975-01-21	Process for isolating thromboplastic material from human placentae
US4177262A (en)	1979-12-04	Plasminogen compositions containing preactivated plasminogens with or without native plasminogens, process for making same, pharmaceutical compositions and control of blood clots
US6268483B1 (en)	2001-07-31	Compositions useful as fibrin sealants
JP2001520198A (ja)	2001-10-30	血小板富有血漿からの成長因子富有化フィブリノーゲン濃縮物の調製
JPS6396132A (ja)	1988-04-27	抗血液凝固物質及びその製法
JP3195439B2 (ja)	2001-08-06	第ｘｉｉｉ因子の精製方法
JPH0672892A (ja)	1994-03-15	ヘモグロビン含有リポソーム

CA2322741A1 - Thrombin preparation and products and fibrin sealant methods employing same - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=22139138

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (16)

Family Cites Families (5)

Cited By (1)

Also Published As

Similar Documents

Legal Events